Invictus Oncology Profile
Key Indicators
- Authorised Capital ₹ 2.10 Cr
as on 11-12-2024
- Paid Up Capital ₹ 2.06 Cr
as on 11-12-2024
- Company Age 13 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 1534.01%
(FY 2022)
- Profit 13.70%
(FY 2022)
- Ebitda 43.76%
(FY 2022)
- Net Worth -3.09%
(FY 2022)
- Total Assets -2.85%
(FY 2022)
About Invictus Oncology
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.10 Cr and a paid-up capital of Rs 2.06 Cr, as per Ministry of Corporate Affairs (MCA) records.
Raghunath Mashelkar, Shiladitya Sengupta, Rajeev Mantri, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232DL2011PTC217394
- Company No.
217394
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Apr 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Invictus Oncology?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jasmin Patel  | Nominee Director | 04-Feb-2013 | Current |
| Raghunath Mashelkar | Director | 04-Feb-2013 | Current |
| Shiladitya Sengupta | Director | 11-Apr-2011 | Current |
| Rajeev Mantri | Nominee Director | 11-Apr-2011 | Current |
Financial Performance and Corporate Structure Insights of Invictus Oncology.
Invictus Oncology Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 1534.01% increase. The company also saw a substantial improvement in profitability, with a 13.7% increase in profit. The company's net worth dipped by a decrease of 3.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Invictus Oncology?
In 2020, Invictus Oncology had a promoter holding of 89.73% and a public holding of 10.26%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vyome Therapeutics LimitedActive 7 years 3 monthsRaghunath Mashelkar and Shiladitya Sengupta are mutual person
Vyome Biosciences Private LimitedActive 14 years 4 monthsShiladitya Sengupta and Rajeev Mantri are mutual person
International Longevity Centre- IndiaActive 16 years 6 monthsRaghunath Mashelkar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Invictus Oncology?
Unlock and access historical data on people associated with Invictus Oncology, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Invictus Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Invictus Oncology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
